Should we be clinically assessing antibody responses to covid vaccines in immunocompromised people?

Competing Interests: Competing interests: Michelle Willicombe has received study support from Oxford Immunotec and is primary investigator for the MELODY study, which received funding from MRC, Kidney Research UK, Vasculitis UK, Blood Cancer UK, and the Cystic Fibrosis Trust. Kidney Care UK has received advisory fees for Fiona Loud’s time from Otsuka (home dialysis), Baxter (patient education), AstraZeneca (on CKD plus one on covid), and Novartis (leadership). Liz Lightstone has received fees for consultancies /advisories for Alexion, AstraZeneca, BMS, Biogen, GSK, Kezar, Novartis, and Pfizer, and been part of speaker bureaux for Alexion and GSK.